lung

12345678910111213141516171819
Across
  1. 1. organization of clinical trials
  2. 3. tumor staging criteria
  3. 8. the response restored by LIBTAYO
  4. 10. method to confirm objective response rate (ORR)
  5. 12. objective response rate. Duration of response. Complete response rate. Safety and tolerability.
  6. 14. generates fully human therapeutic antibodies, including LIBTAYO
  7. 16. criteria used to select patients for clinical trials
  8. 17. approves drug indications
  9. 18. Information resource that contains efficacy, safety, and usage information for LIBTAYO
  10. 19. 360 mg infusion, every 3 weeks
Down
  1. 2. LIBTAYO______ enhances patient access to LIBTAYO
  2. 4. number of approved FDA indications for LIBTAYO
  3. 5. immune function inhibited by LIBTAYO
  4. 6. administration method of LIBTAYO
  5. 7. expresses programmed death receptor
  6. 8. LIBTAYO biologic
  7. 9. first line immune response
  8. 11. color of LIBTAYO
  9. 13. action taken when a patient experiences a severe adverse reaction
  10. 15. profile in which adverse reactions are reported